Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Breast Neoplasms

Breast Neoplasms

Brain Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Adenocarcinoma, Rectal Neoplasms

Colorectal Neoplasms

Breast Neoplasms, Meningeal Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Breast Neoplasms

Colonic Neoplasms

Brain Neoplasms, Neoplasm Metastasis

Brain Neoplasms

Breast Neoplasms

Meningeal Neoplasms, Meningeal Carcinomatosis

Metastatic Breast Cancer With a Isolated Brain Progression

Anatomic Stage IA Breast Cancer AJCC v8

Breast Neoplasms, Meningeal Neoplasms

Breast Neoplasms

Breast Neoplasms

Anatomic Stage II Breast Cancer AJCC v8

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

HER2-positive Breast Cancer

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Breast Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Brain Neoplasms

Breast Neoplasms

Clinical Trials

TAPUR

JAZMINE

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

BRIDGET

I-SPY

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

H3RAKLES

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

ERASE-CRC

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

TrasTUCAN

ETIC-LM

InTTercePT

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

TUGETHER

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

PRE-I-SPY-PI

TUC-TOC

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

TRAIN-4

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

2019-101826

MARGARET

TOPAZ

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC